Neuropore Therapies and UCB have entered into a world-wide collaboration and agreement to develop and commercialize therapeutic products aiming at slowing the progression of Parkinson’s disease Read the full story

UCB Group is selling Kremers Urban Pharmaceuticals, to two private equity firms, Advent International and Avista Capital Partners, for $1.525 billion Read the full story

IMS Health becomes pharma partner with UCB to help deliver greater business insights and improved operations, leveraging IMS Health’s Nexxus Commercial Application Suite and the IMS One intelligent cloud. Read the full story

UCB and Dermira have entered into an exclusive pharma licensing agreement for the development and future commercialization of Cimzia (certolizumab pegol) in dermatology. Read the full story

The term 'top pharma' can relate to the top pharmaceutical companies or the top 10 or 50... Read the full story

UCB is a top pharmaceutical company based in Brussels, Belgium Read the full story

Sanofi and UCB have entered into a pharma deal for the discovery and development of innovative anti-inflammatory small molecules, which have the potential to treat a wide range of immune-mediated diseases in areas such as gastroenterology and arthritis. Read the full story

Vectura Group have entered into a collaboration for the co development of an innovative biologic immunomodulatory product in the area of severe inflammatory respiratory disease Read the full story

UCB, a top pharmaceutical company, is reviewed in terms of partnering, licensing and M&A interests and activity over recent years Read the full story

UCB big pharma deals IBM and announces the completion of the initial phase of a project designed to harness the power of analytics to help healthcare providers deliver more highly personalized care to people living with epilepsy. Read the full story